Fig. 1: Consort diagram for the T-DM1/Pertuzumab, THP, and control populations. | Nature Communications

Fig. 1: Consort diagram for the T-DM1/Pertuzumab, THP, and control populations.

From: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Fig. 1

Consort diagram shows the number of patients screening, randomized, and receiving allocated therapy from the start of I-SPY2 to the close of the T-DM1/Pertuzumab and THP arms. I-SPY2 is modified intent-to-treat, where patients receiving their allocated therapy are considered evaluable for analysis.

Back to article page